These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clopidogrel desensitization: case report and review of published protocols. Owen P; Garner J; Hergott L; Page RL Pharmacotherapy; 2008 Feb; 28(2):259-70. PubMed ID: 18225971 [TBL] [Abstract][Full Text] [Related]
3. Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience. Walker NE; Fasano MB; Horwitz PA J Invasive Cardiol; 2006 Jul; 18(7):341-4. PubMed ID: 16816444 [TBL] [Abstract][Full Text] [Related]
4. Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity. Walker NE; Fasano MB; Hobbs RA; Horwitz PA Crit Pathw Cardiol; 2007 Mar; 6(1):26-9. PubMed ID: 17667884 [TBL] [Abstract][Full Text] [Related]
5. Clopidogrel hypersensitivity: a novel multi-day outpatient oral desensitization regimen. Fajt M; Petrov A Ann Pharmacother; 2010 Jan; 44(1):11-8. PubMed ID: 20009004 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy and tolerability of a clopidogrel desensitization protocol]. Estefanell-Tejero A; López-Cabezas C; Riu-Viladoms G; Falces-Salvador C Med Clin (Barc); 2012 May; 138(15):684-5. PubMed ID: 22015006 [No Abstract] [Full Text] [Related]
7. Desensitization to clopidogrel: a tailor-made protocol. Barreira P; Cadinha S; Malheiro D; Moreira da Silva JP Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):53-5. PubMed ID: 24702878 [TBL] [Abstract][Full Text] [Related]
8. Clopidogrel desensitization after drug-eluting stent placement. von Tiehl KF; Price MJ; Valencia R; Ludington KJ; Teirstein PS; Simon RA J Am Coll Cardiol; 2007 Nov; 50(21):2039-43. PubMed ID: 18021870 [TBL] [Abstract][Full Text] [Related]
9. Management of clopidogrel hypersensitivity without drug interruption. Campbell KL; Cohn JR; Fischman DL; Walinsky P; Mallya R; Jaffrani W; Savage MP Am J Cardiol; 2011 Mar; 107(6):812-6. PubMed ID: 21247516 [TBL] [Abstract][Full Text] [Related]
10. Allergic reactions to clopidogrel and cross-reactivity to other agents. Lokhandwala J; Best PJ; Henry Y; Berger PB Curr Allergy Asthma Rep; 2011 Feb; 11(1):52-7. PubMed ID: 20941557 [TBL] [Abstract][Full Text] [Related]
11. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. Cheema AN; Mohammad A; Hong T; Jakubovic HR; Parmar GS; Sharieff W; Garvey MB; Kutryk MJ; Fam NP; Graham JJ; Chisholm RJ J Am Coll Cardiol; 2011 Sep; 58(14):1445-54. PubMed ID: 21939827 [TBL] [Abstract][Full Text] [Related]
12. Immediate hypersensitivity and delayed hypersensitivity to clopidogrel. Gutiérrez-Fernández D; Fuentes-Vallejo MS; Rueda-Ygueravides MD; Foncubierta-Fernández A; León-Jiménez A Allergol Immunopathol (Madr); 2007; 35(5):213-5. PubMed ID: 17923076 [TBL] [Abstract][Full Text] [Related]
13. Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol. Bulva J; Simon RA Curr Vasc Pharmacol; 2019; 17(2):113-118. PubMed ID: 30378498 [TBL] [Abstract][Full Text] [Related]
14. Use of prasugrel in a patient with clopidogrel hypersensitivity. Peppard SR; Held-Godgluck BM; Beddingfield R Ann Pharmacother; 2011 Oct; 45(10):e54. PubMed ID: 21896923 [TBL] [Abstract][Full Text] [Related]
16. Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy. Chopra P; Verma P; Klaustermeyer WB Ann Allergy Asthma Immunol; 2011 Dec; 107(6):541-2. PubMed ID: 22123386 [No Abstract] [Full Text] [Related]
18. [Desensitization versus clinical tolerance]. Matheu V; González-Pérez R; Poza P; Sánchez-Machín I Med Clin (Barc); 2013 May; 140(9):428-9. PubMed ID: 23339886 [No Abstract] [Full Text] [Related]
19. Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy. Page NA; Schroeder WS Ann Pharmacother; 2007 Jan; 41(1):61-7. PubMed ID: 17200429 [TBL] [Abstract][Full Text] [Related]
20. Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach. Cheema AN Curr Vasc Pharmacol; 2019; 17(2):119-122. PubMed ID: 30124155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]